Management of Patients with MYC-Altered Lymphomas.

about

High expressions of BCL6 and Lewis y antigen are correlated with high tumor burden and poor prognosis in epithelial ovarian cancer.

P2860

Q48625336-4BA6E0E3-05F6-4332-8807-FAD5E686CD7C

P2860

Management of Patients with MYC-Altered Lymphomas.

Item

http://www.wikidata.org/entity/Q35960027

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Management of Patients with MYC-Altered Lymphomas.

@ast

Management of Patients with MYC-Altered Lymphomas.

@en

type

Item

label

Management of Patients with MYC-Altered Lymphomas.

@ast

Management of Patients with MYC-Altered Lymphomas.

@en

prefLabel

Management of Patients with MYC-Altered Lymphomas.

@ast

Management of Patients with MYC-Altered Lymphomas.

@en

P1476

Management of Patients with MYC-Altered Lymphomas.

@en

P2093

Daniel J Landsburg

http://www.w3.org/2001/XMLSchema#string

P2860

Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas

ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia.

BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.

Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era

Complete response to induction therapy in patients with Myc-positive and double-hit non-Hodgkin lymphoma is associated with prolonged progression-free survival

Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma.

B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.

Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.

Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?

P2888

s11899-016-0320-7

P304

208-217

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11899-016-0320-7

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-03-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26983958

http://www.w3.org/2001/XMLSchema#string

Management of Patients with MYC-Altered Lymphomas.

about

P2860

P2860

Management of Patients with MYC-Altered Lymphomas.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698